Statement: None of the patients in the primary trial or the secondary trial committed suicide.
Primary_evidence: Adverse Events 1:   Total: 6   Atrial fibrillation 1/67 (1.49%)   Ventricular fibrillation 1/67 (1.49%)   Gastrointestinal perforation 1/67 (1.49%)   Periproctitis 1/67 (1.49%)   General physical health deterioration 1/67 (1.49%)   Escherichia sepsis 1/67 (1.49%)   Pneumonia 1/67 (1.49%)   Tumour pain 1/67 (1.49%)   Renal failure acute 1/67 (1.49%)   Pleurisy 1/67 (1.49%)
Secondary_evidence: Adverse Events 1:   Total: 5/32 (15.63%)   Leukopenia 1/32 (3.13%)   Neutropenia 1/32 (3.13%)   Cataract 1/32 (3.13%)   Infection 1/32 (3.13%)   Upper respiratory tract infection 1/32 (3.13%)   Completed suicide 1/32 (3.13%)